In 2022, Michel Vounatsos earned $7.88M in total compensation at Biogen, including $153.85K salary and $7.73M in stock. Led Biogen as CEO for 6 years.
Compensation History
Annual executive compensation data for Michel Vounatsos, including salary, bonuses, and stock awards.
Year
2022
Total Compensation
$7.88M
Salary
$153.85K
Bonus
$0.00
Other
$0.00
Salary
$153.85KBoard Justification
The compensation philosophy emphasizes alignment with stockholder interests and performance-based rewards.
Bonus
$0.00Board Justification
No bonus was paid for 2022 due to termination before the end of the performance period.
Other Compensation
$0.00Board Justification
No additional compensation was reported for 2022.
Restricted Stock
Board Justification
35,687 shares of RSUs vested in 2022, based on the prorated vesting agreement following termination.
Performance Metrics
Performance metrics for 2022 included financial performance goals that were not achieved due to the CEO's termination.
Michel Vounatsos
Ex-CEO of Biogen
Education
N/A
Field of Expertise
Healthcare & Life Sciences - Biotechnology
Sector of Economy
Healthcare
Born
January 1, 1964 - 61 years ago
CEO of Biogen for
6 years 4 months (Jul 2016 - Nov 2022)
Previous Experience
Chief Executive Officer of Biogen
Holdings
Track Michel Vounatsos's stock holdings and portfolio value over time.
Insider Trading
Michel Vounatsos's recent stock transactions, purchases, and sales filed with the SEC.
No insider trades found for this CEO.
Rivals
Compare Michel Vounatsos with competitor CEOs and industry peers.
Daniel O'Day
CEO of Gilead Sciences
2024 Compensation
Stock
$18.79M
Salary
$1.77M
Bonus
$0.00
Other
$1.34M
Total Holdings
$23.48M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
Christopher Boerner
CEO of Bristol-Myers Squibb
2023 Compensation
Stock
$0.00
Salary
$1.50M
Bonus
$0.00
Other
$311.64K
Total Holdings
$7.39M
Reshma Kewalramani
CEO of Vertex Pharmaceuticals
2022 Compensation
Stock
$10.64M
Salary
$1.40M
Bonus
$3.78M
Other
$43.06K
Total Holdings
$50.74M
Robert A. Bradway
CEO of Amgen
2024 Compensation
Stock
$0.00
Salary
$1.87M
Bonus
$0.00
Other
$714.33K
Total Holdings
$269.12M
Brett P. Monia, Ph.D.
Founder and CEO of Ionis Pharmaceuticals
2023 Compensation
Stock
$430.00K
Salary
$650.00K
Bonus
$300.00K
Other
$50.00K
Total Holdings
$6.01M